Form 8-K - Current report:
SEC Accession No. 0001437749-24-035542
Filing Date
2024-11-18
Accepted
2024-11-18 08:20:42
Documents
16
Period of Report
2024-11-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20241115c_8k.htm   iXBRL 8-K 28937
2 EXHIBIT 99.1 ex_748830.htm EX-99.1 18577
7 moleculin01.jpg GRAPHIC 12642
  Complete submission text file 0001437749-24-035542.txt   220491

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20241118.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20241118_def.xml EX-101.DEF 11425
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20241118_lab.xml EX-101.LAB 15311
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20241118_pre.xml EX-101.PRE 11585
18 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20241115c_8k_htm.xml XML 2834
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 241469813
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)